A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors
Latest Information Update: 12 Jun 2024
At a glance
- Drugs TOS-358 (Primary)
- Indications Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors Totus Medicines
- 19 Apr 2023 Trial design presented at the 114th Annual Meeting of the American Association for Cancer Research
- 13 Apr 2023 According to a Totus Medicines media release, the first patient has been dosed in the study.
- 10 Apr 2023 According to a Totus Medicines media release, company will be presenting poster presentation for this trial at the American Association for Cancer Research (AACR) Annual Meeting, Abstract: CT249, on Tuesday April 18 at 1:30 PM - 5:00 PM ET.full abstracts will be available on the AACR and Totus Website.